News Quantified

LOGC – contextlogic inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial Results

ContextLogic Completes $907.5 Million Acquisition of US Salt, Marking Transformation into Business Ownership Platform

ContextLogic Advances US Salt Acquisition with Launch of Fully Backstopped $115 Million Rights Offering Priced at $8.00 per share

ContextLogic: Why We Exited But Continue To Follow Closely [Seeking Alpha]

ContextLogic Makes Its Move [Seeking Alpha]

Form 4 ContextLogic Holdings For: Mar 09 Filed by: Bobbili Raja

Form 4 ContextLogic Holdings For: Feb 26 Filed by: Bobbili Raja

Form 4 ContextLogic Holdings For: Feb 26 Filed by: ABRAMS CAPITAL, LLC

Form 4 ContextLogic Holdings For: Feb 26 Filed by: Abrams David C

Form 3 ContextLogic Holdings For: Feb 26 Filed by: Bobbili Raja

Top News Gainers

3/17 LogicBio Therapeutics Inc (NASDAQ: LOGC) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock. 31.5%

2/11 EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against LogicBio Therapeutics, Inc. – LOGC 14.6%

4/29 Form DEF 14A LogicBio Therapeutics, For: Jun 19 10.9%

2/18 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 10.8%

3/18 EQUITY ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. – LOGC 9.6%

8/13 Q2/2019 6/30/2019 EPS -0.450 ZacksConsensus -0.410 ActVsEst (0.040) - Miss 8.0%

4/23 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC 6.1%

3/23 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm – LOGC 6.0%

6/27 Form 8-K LogicBio Therapeutics, For: Jun 25 4.8%

8/29 Form 4 LogicBio Therapeutics, For: Aug 27 Filed by: Wilton Thomas 4.4%

Top News Decliners

2/10 LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia -32.0%

8/13 Form 10-Q LogicBio Therapeutics, For: Jun 30 -15.7%

8/13 LogicBio up 20% ahead of IND filing for lead gene therapy candidate [Seeking Alpha] -11.9%

3/19 Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against LogicBio Therapeutics, Inc. (LOGC) -11.3%

3/27 LOGICBIO THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against LogicBio Therapeutics, Inc -11.2%

8/10 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.7%

8/23 LogicBio Therapeutics Inc (NASDAQ: LOGC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.2%

4/25 ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds LogicBio Therapeutics, Inc. Investors of the Important Deadline in Securities Class Action First Filed by Firm – LOGC -10.1%

2/21 LogicBio Therapeutics Inc (NASDAQ: LOGC) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -9.2%

6/24 Form 8-K LogicBio Therapeutics, For: Jun 24 -9.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day